Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms

Schizophrenia Bulletin

Volumn 29, Issue 3, 2003, Pages 541-546

  Silver, Henry ^a,b   Aharon, Nelson ^c   Kaplan, Alla ^c  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Flugelman (Mazra) Psychiat Hospital   (Israel)

Author keywords

Augmentation treatment; Fluvoxamine; Negative symptoms; Response analysis; Schizophrenia; Side effects; SSRI

Indexed keywords

FLUVOXAMINE; NEUROLEPTIC AGENT; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; DEPRESSION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0242269312     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007026     Document Type: Article

References (25)

1. Andreasen, N.C. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa, 1983.
2. Andreasen, N.C. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa, 1984.
3. Andreasen, N.C.; Arndt, S.; Miller, D.; Flaum, M.; and Nopoulos, P. Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: An overview and update. Psychopathology, 28:7-17, 1995.
4. Carpenter, W.T.; Heinrichs, D.W.; and Wagman, A.M.I. Deficit and nondeficit forms of schizophrenia. American Journal of Psychiatry, 145:578-583, 1988.
5. Czobor, P.; Bitter, I.; and Volavka, J. Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: A study of their correlation and redundancy. Psychiatry Research, 36:129-139, 1991.
6. Fenton, W.S., and McGlashan, T.H. Testing systems for assessment of negative symptoms in schizophrenia. Archives of General Psychiatry, 49:179-184, 1992.
7. Goff, D.C.; Midha, K.K.; Sarid-Segal, O.; Hubbard, J.W.; and Amico, E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology, 117:417-423, 1995.
8. Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23:56-62, 1960.
9. Herbener, E.S., and Harrow, M. Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients. Schizophrenia Bulletin, 27(3):527-537, 2001.
10. Kelley, M.E.; van Kammen, D.P.; and Allen, D.N. Empirical validation of primary negative symptoms: Independence from effects of medication and psychosis. American Journal of Psychiatry, 156:406-411, 1999.
11. Mueser, K.T.; Sayers, S.L.; Schooler, N.R.; Mance, R.M.; and Haas, G.L. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms American Journal of Psychiatry, 151:1453-1462, 1994.
12. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale (BPRS). Psychological Reports, 10:799-812, 1962.
13. Peralta, V.; Cuesta, M.J.; Martinez-Larrea, A.; and Serrano, J.F. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. American Journal of Psychiatry, 157:1461-1466, 2000.
14. Silver, H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Reviews, 7:283-304, 2001.
15. Silver, H.; Barash, I.; Aharon, N.; Kaplan, A.; and Poyurovsky, M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo-controlled study. International Clinical Psychopharmacology, 15:257-261, 2000.
16. Silver, H., and Nassar, A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add on double blind placebo controlled study. Biological Psychiatry, 31:698-704, 1992.
17. Silver, H., and Shmugliakov, N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. Journal of Clinical Psychopharmacology, 18:208-211, 1998.
18. Simpson, G.M., and Angus, J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212(Suppl):11-19, 1970.
19. Spina, E.; Avenoso, A.; Facciola, G.; Fabrazzo, M.; Monteleone, P.; Maj, M.; Perucca, E.; and Caputi, A.P. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. International Clinical Psychopharmacology, 13:141-145, 1998.
20. Spina, E.; De Domenico, P.; Ruello, C.; Longobardo, N.; Gitto, C.; Ancione, M.; Di Rosa, A.E.; and Caputi, A.P. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. International Clinical Psychopharmacology, 9:281-285, 1994.
21. Spina, E.; Pollicino, A.M.; Avenoso, A.; Campo, G.M.; and Caputi, A.P. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. International Journal of Clinical Pharmacology Research, 13:167-171, 1993.
22. SPSS. SPSS 10 for Windows. Chicago, IL: SPSS, 2000.
23. Strauss, J.S.; Carpenter, W.T., Jr.; and Bartko, J.J. The diagnosis and understanding of schizophrenia: III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophrenia Bulletin, 11:61-69, 1974.
24. Toomey, R.; Kremen, W.S.; Simpson, J.C.; Samson, J.A.; Seidman, L.J.; Lyons, M.J.; Faraone, S.V.; and Tsuang, M.T. Revisiting the factor structure for positive and negative symptoms: Evidence from a large heterogeneous group of psychiatric patients. American Journal of Psychiatry, 1154:371-377, 1997.
25. Welham, J.; Stedman, T.; and Clair, A. Choosing negative symptom instruments: Issues of representation and redundancy. Psychiatry Research, 87:47-56, 1999.